OTC Markets OTCQB - Delayed Quote USD

MediPharm Labs Corp. (MEDIF)

Compare
0.0550 -0.0032 (-5.50%)
At close: October 21 at 4:00 PM EDT
Currency in CAD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
37,757.0000
33,062.0000
22,117.0000
21,711.0000
36,012.0000
--
Cost of Revenue
27,075.0000
27,207.0000
24,031.0000
36,957.0000
79,990.0000
--
Gross Profit
10,682.0000
5,855.0000
-1,914.0000
-15,246.0000
-43,978.0000
--
Operating Expense
23,765.0000
23,602.0000
26,870.0000
27,763.0000
27,736.0000
--
Operating Income
-13,083.0000
-17,747.0000
-28,784.0000
-43,009.0000
-71,714.0000
--
Net Non Operating Interest Income Expense
255.0000
475.0000
448.0000
-10,281.0000
-7,602.0000
--
Other Income Expense
-5,599.0000
3,913.0000
-1,653.0000
-1,398.0000
7,216.0000
--
Pretax Income
-13,584.0000
-13,359.0000
-29,989.0000
-54,688.0000
-72,100.0000
--
Tax Provision
7.0000
-276.0000
-6.0000
113.0000
-4,990.0000
--
Net Income Common Stockholders
-13,308.0000
-13,083.0000
-29,983.0000
-54,801.0000
-66,353.0000
--
Diluted NI Available to Com Stockholders
-13,308.0000
-13,083.0000
-29,983.0000
-54,801.0000
-66,353.0000
--
Basic EPS
-0.04
-0.04
-0.11
-0.22
-0.48
--
Diluted EPS
-0.04
-0.04
-0.11
-0.22
-0.48
--
Basic Average Shares
399,586.6050
363,323.9520
276,861.1090
249,906.8040
138,549.2640
--
Diluted Average Shares
399,586.6050
363,323.9520
276,861.1090
249,906.8040
138,549.2640
--
Total Operating Income as Reported
-13,588.0000
-18,252.0000
-29,533.0000
-48,916.0000
-72,576.0000
--
Rent Expense Supplemental
1,498.0000
1,300.0000
586.0000
366.0000
709.0000
--
Total Expenses
50,840.0000
50,809.0000
50,901.0000
64,720.0000
107,726.0000
--
Net Income from Continuing & Discontinued Operation
-13,308.0000
-13,083.0000
-29,983.0000
-54,801.0000
-66,353.0000
--
Normalized Income
-12,552.0000
-16,915.1565
-28,330.3307
-53,773.4700
-73,069.5847
--
Interest Income
825.0000
840.0000
479.0000
225.0000
273.0000
--
Interest Expense
570.0000
365.0000
31.0000
10,506.0000
7,875.0000
--
Net Interest Income
255.0000
475.0000
448.0000
-10,281.0000
-7,602.0000
--
EBIT
-13,014.0000
-12,994.0000
-29,958.0000
-44,182.0000
-64,225.0000
--
EBITDA
-10,159.0000
-10,478.0000
-27,086.0000
-38,549.0000
-53,418.0000
--
Reconciled Cost of Revenue
27,075.0000
25,144.0000
21,990.0000
32,738.0000
71,055.0000
--
Reconciled Depreciation
2,855.0000
2,516.0000
2,872.0000
5,633.0000
10,807.0000
--
Net Income from Continuing Operation Net Minority Interest
-13,308.0000
-13,083.0000
-29,983.0000
-54,801.0000
-66,353.0000
--
Total Unusual Items Excluding Goodwill
-756.0000
3,913.0000
-1,653.0000
-1,398.0000
7,216.0000
--
Total Unusual Items
-756.0000
3,913.0000
-1,653.0000
-1,398.0000
7,216.0000
--
Normalized EBITDA
-9,403.0000
-14,391.0000
-25,433.0000
-37,151.0000
-60,634.0000
--
Tax Rate for Calcs
--
0.0000
0.0000
0.0003
0.0001
--
Tax Effect of Unusual Items
--
80.8435
-0.3307
-370.4700
499.4153
--
12/31/2019 - 1/8/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers